BRIEF published on 04/07/2026 at 07:05, 3 months 6 days ago Aelis Farma obtient une subvention de 458 000 € pour son programme de lutte contre l'obésité France 2030 Aelis Farma Récepteur CB1 Recherche Sur L'obésité Subvention De Nouvelle-Aquitaine
BRIEF published on 04/07/2026 at 07:05, 3 months 6 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 3 months 6 days ago Informations privilégiées / Autres communiqués Aelis Farma reçoit 458 k€ de subvention de France 2030 en Nouvelle-Aquitaine pour son programme innovant dans l'obésité et les maladies métaboliques. Soutien non dilutif pour la recherche sur les traitements des désordres métaboliques Subvention France 2030 Obésité Aelis Farma Nouvelle-Aquitaine
PRESS RELEASE published on 04/07/2026 at 07:00, 3 months 6 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 3 months 23 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
BRIEF published on 03/21/2026 at 10:10, 3 months 23 days ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
PRESS RELEASE published on 03/21/2026 at 10:05, 3 months 23 days ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
PRESS RELEASE published on 03/21/2026 at 10:05, 3 months 23 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 6 months 1 day ago Aelis Farma obtient un avis favorable de l'EMA pour AEF0217 dans la trisomie 21 EMA Aelis Farma Trisomie 21 AEF0217 Développement Pédiatrique
BRIEF published on 01/12/2026 at 07:35, 6 months 1 day ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
Published on 07/14/2026 at 01:45, 4 hours 13 minutes ago Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 5 hours 57 minutes ago Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 6 hours 48 minutes ago Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 8 hours 23 minutes ago ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 9 hours 58 minutes ago IBC Announces Share-Based Compensation to Directors
Published on 07/14/2026 at 04:45, 1 hour 13 minutes ago Asia’s Debut of LEAP East in HKCEC Marks Hong Kong’s Largest Inaugural Tech Summit
Published on 07/13/2026 at 22:30, 7 hours 28 minutes ago Half-year 2026 Results Media and Investor Conference Call and Webcast
Published on 07/13/2026 at 21:20, 8 hours 38 minutes ago Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 21:17, 8 hours 40 minutes ago EQS-Adhoc: Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 20:48, 9 hours 10 minutes ago EQS-Adhoc: Gateway Real Estate AG: Forecast for the financial year 2026
Published on 07/13/2026 at 18:00, 11 hours 58 minutes ago CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 11 hours 58 minutes ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 11 hours 58 minutes ago THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
